
· updated
FDA Peptide Interim Access Policy: What the Oct 15 Step Means
Update, Oct 30, 2026: the policy text is out. HHS filed it on Oct 28, covering BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Read what the HHS peptide policy actually says. The article below is kept as written on Oct 16.
The plan to bring peptides like BPC-157 into regulated pharmacies just moved from rumor to paperwork. On Thursday, Oct 15, 2026, the FDA and its parent agency HHS sent an “interim access policy for compounding using certain peptides” to the White House for review, according to a filing on the Office of Management and Budget (OMB) website. The filing has no details, and the policy is not in effect yet. But it is the first official step since the July advisory vote, and it points toward a legit, prescription-based path instead of the gray market.
Key facts
- Oct 15, 2026: HHS and the FDA submitted an “interim access policy for compounding using certain peptides” to OMB, the White House office that reviews rules with potentially significant economic impact.
- No details in the filing: two people familiar with the plan told the Associated Press it would let pharmacies compound some popular peptides, including BPC-157. Officials have not confirmed the list.
- How it would work: through “enforcement discretion,” meaning the FDA would choose not to act against compounding pharmacies making certain peptides.
- Background: in July 2026 the FDA’s compounding advisory committee recommended 6 of 7 peptides for the 503A Bulks List, with BPC-157, KPV and TB-500 at 8-6 and MOTS-c at 7-5.
- Still not approved: none of these peptides has been approved by the FDA as safe or effective, and permanent rules would still need formal rulemaking.
What did the FDA actually send to the White House?
A one-line entry. Reuters reported that the OMB filing names the “interim access policy for compounding using certain peptides” and “does not provide any details.” HHS and the FDA did not immediately comment, and an administration official declined to comment.
What we know about the content comes from reporting. The AP, citing two people who spoke anonymously, said the policy would let pharmacies temporarily compound some of the most popular peptides, including BPC-157, the one people at the gym call “Wolverine.” The AP report names only BPC-157, so the full list is still unknown. On Oct 7 the Washington Post had reported a draft plan covering 7 previously restricted peptides, which we covered in our 503A vs 503B explainer.
What is an “interim access policy”?
It is a stopgap, not a new law. Under section 503A, a compounding pharmacy can only use a raw ingredient (a “bulk drug substance”) that meets one of three tests, and for most gym-talk peptides the only realistic test is being on the FDA’s 503A Bulks List. Getting on that list takes notice-and-comment rulemaking: a proposed rule, public comments, then a final rule.
The FDA already uses interim policies while it works through that list. Its own page says the agency “developed an interim policy describing conditions under which the agency does not intend to take action” against compounders using certain nominated substances, so patient treatment is not disrupted during review. The new policy, as described by the AP, would apply the same idea to certain peptides: pharmacies would be told they will not be targeted for making them while permanent rules are written.
Why this is good news, honestly
The case for it is simple. Right now a lot of people get peptides from online sellers whose vials are labeled for lab research, often made overseas, with no prescription and no pharmacy standing behind the vial. HHS Secretary Robert F. Kennedy Jr. has argued that compounding pharmacies must be allowed to supply peptides because Americans are turning to “gray market” versions made in China and other countries. A pharmacy route means a licensed prescriber, a state-licensed pharmacy, a label with a patient name, and someone accountable if something goes wrong.
It also gives the market a clearer lane. Telehealth companies Hims & Hers and Noom have both said they plan to offer peptides if federal rules allow it, and Wall Street analysts cited by the AP estimate the market at $2 billion to $3 billion.
The honest caveats
Access and proof are different things, and the reporting is clear on the limits:
- Evidence is thin. Most of the data on these peptides comes from animal studies. FDA staff scientists recommended against all seven in July, describing the studies as “short in duration, small in sample size.” Our BPC-157 profile grades the evidence D, and the evidence review shows how little human data there is.
- The FDA had safety concerns. The agency previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances too risky to compound. Per the FDA, possible risks include contamination, allergic reactions and tumor growth.
- The panel was not neutral territory. The AP reports the July panel was selected by HHS and included doctors, pharmacists and consultants who work in the peptide field.
- It is temporary by design. Formally adding peptides to the Bulks List still requires federal rulemaking, which the AP says could take years and several rounds of public comment. It is unclear whether the administration plans to pursue it. The FDA’s last finished 503A Bulks List rule dates to February 2019.
- Timing is open. OMB review comes first, and the policy could change before it is published.
For the vote-by-vote breakdown, see our PCAC vote results.
Does this make BPC-157 legal right now?
Not yet. As of Oct 16, 2026, the policy is under White House review and has not been published or put into effect. BPC-157 is off the FDA’s Category 2 restricted list and has a positive advisory vote, but it is not FDA-approved and it is not a legal over-the-counter supplement. Our live legal status tracker will update the day the policy is published.
What it means for you
If this policy lands the way it has been reported, the legitimate path to a peptide like BPC-157 will look like any other compounded prescription: a licensed provider evaluates you, writes a prescription, and a licensed compounding pharmacy fills it with your name on the label. Expect cash prices, since payers generally treat compounded drugs as outside standard coverage. A product with no prescription and a “not for human use” label stays outside that path whatever the news says. If a peptide is on your radar, talk to a licensed provider about whether it makes sense for you, and read how peptides get prescribed so you know what a legit process looks like.
Sources
- Reuters via Yahoo News: US FDA takes step to change peptide compounding policy (Oct 15, 2026)
- NBC News / Associated Press: Trump administration advances plan for peptide drugs favored by RFK Jr. (Oct 16, 2026)
- AJMC: FDA panel backs 6 peptides for compounding (July 2026)
- FDA: Bulk drug substances used in compounding under section 503A (current as of May 14, 2026)
Educational content only, not medical advice or legal advice. Talk to a licensed provider about whether any medicine is right for you.